Active Ingredient History

  • Now
Nelotanserin is a drug developed by Arena Pharmaceuticals which acts as an inverse agonist on the serotonin receptor subtype 5-HT2A and was under development for the treatment of insomnia. It was shown to be effective and well tolerated in clinical trials, but development was halted in December 2008 because the substance did not meet the trial's effectiveness endpoints. Research continues on newer analogues which may potentially be more successful. More recently, nelotanserin has been repurposed for the treatment of Lewy body disease. As of 2017, it is in phase II clinical trials for this indication.   Wikipedia

  • SMILES: COc1ccc(NC(=O)Nc2ccc(F)cc2F)cc1c3c(Br)cnn3C
  • Mol. Mass: 437.24
  • ALogP: 4.78
  • ChEMBL Molecule:
More Chemistry
apd125 | apd-125 | nelotanserin


Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue